De-Risking Early Dermatology Development Through Clinical Pharmacology Models
- Validating inflammatory pathways in vivo using inducible skin challenge models, enabling direct proof-of-mechanism in healthy participants where baseline disease activity is absent, building early confidence that targets are biologically active before committing to patient trials
- Benchmarking multi-pathway modulation against approved single-target therapies to allow mechanistic differentiation and strengthen scientific rationale and prioritisation
- Leveraging phase 0–1 experimental therapeutics data to engage regulators and investigators, translating mechanistic evidence into credible narratives for Phase II readiness, reducing downstream development risk and accelerating progression into patient populations such as HS